Matthew J Matasar1, Jennifer S Ford2, Elyn R Riedel2, Talya Salz2, Kevin C Oeffinger2, David J Straus2. 1. Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY (MJM, DJS); Department of Medicine, Weill Cornell Medical College, New York, NY (MJM, DJS); Adult Survivorship Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY (MJM, KCO); Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY (JSF); Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY (ERR, TS); Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY (JSF, KCO). matasarm@mskcc.org. 2. Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY (MJM, DJS); Department of Medicine, Weill Cornell Medical College, New York, NY (MJM, DJS); Adult Survivorship Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY (MJM, KCO); Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY (JSF); Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY (ERR, TS); Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY (JSF, KCO).
Abstract
BACKGROUND: Survivors of Hodgkin's lymphoma (HL) treated as adults are at risk for late effects of therapy. However, the burden of late morbidity and mortality among adults treated for HL remains incompletely characterized. METHODS: Vital status and, for deceased, cause of death were determined for 746 adults treated on a first-line trial at a single center from 1975 to 2000. Survivors completed a detailed survey describing their physical and mental health. A severity score (grades 1-4, ranging from mild to life-threatening or disabling) was assigned to self-reported conditions. RESULTS: At a median follow-up of 22 years, 227 of patients (30.4%) had died, 107 (47.1%) from HL, 120 (52.9%) from other causes, including second primary malignancies (SPMs) (n = 52) and cardiovascular disease (n = 27). Across the duration of follow-up, all-cause and SPM-specific risk of death remained higher than predicted by normative data. Among survivors, late morbidity survey data are available for 238 patients (45.9%). Ninety-four-point-one percent of respondents reported at least one morbidity, and 47.5% reported at least one grade 3 or 4 morbidity; 20.2% reported two or more grade 3 morbidities. Commonly reported morbidities included cardiovascular (54.6%), endocrine (68.5%), pulmonary disease (21.4%), and nonfatal second malignancy (23.1%). Anxiety, depression, and fear of recurrence were frequently reported. CONCLUSIONS: Among a large cohort of patients treated for HL with extensive follow-up, risk of late mortality from causes other than HL and prevalence of late medical morbidity are high. Guidelines for prevention, screening, and management of late effects in adult survivors of HL are needed.
BACKGROUND: Survivors of Hodgkin's lymphoma (HL) treated as adults are at risk for late effects of therapy. However, the burden of late morbidity and mortality among adults treated for HL remains incompletely characterized. METHODS: Vital status and, for deceased, cause of death were determined for 746 adults treated on a first-line trial at a single center from 1975 to 2000. Survivors completed a detailed survey describing their physical and mental health. A severity score (grades 1-4, ranging from mild to life-threatening or disabling) was assigned to self-reported conditions. RESULTS: At a median follow-up of 22 years, 227 of patients (30.4%) had died, 107 (47.1%) from HL, 120 (52.9%) from other causes, including second primary malignancies (SPMs) (n = 52) and cardiovascular disease (n = 27). Across the duration of follow-up, all-cause and SPM-specific risk of death remained higher than predicted by normative data. Among survivors, late morbidity survey data are available for 238 patients (45.9%). Ninety-four-point-one percent of respondents reported at least one morbidity, and 47.5% reported at least one grade 3 or 4 morbidity; 20.2% reported two or more grade 3 morbidities. Commonly reported morbidities included cardiovascular (54.6%), endocrine (68.5%), pulmonary disease (21.4%), and nonfatal second malignancy (23.1%). Anxiety, depression, and fear of recurrence were frequently reported. CONCLUSIONS: Among a large cohort of patients treated for HL with extensive follow-up, risk of late mortality from causes other than HL and prevalence of late medical morbidity are high. Guidelines for prevention, screening, and management of late effects in adult survivors of HL are needed.
Authors: Anthony J Swerdlow; Craig D Higgins; Paul Smith; David Cunningham; Barry W Hancock; Alan Horwich; Peter J Hoskin; T Andrew Lister; John A Radford; Ama Z S Rohatiner; David C Linch Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Günther Schellong; Marianne Riepenhausen; Christian Bruch; Stefan Kotthoff; Johannes Vogt; Tobias Bölling; Karin Dieckmann; Richard Pötter; Achim Heinecke; Jürgen Brämswig; Wolfgang Dörffel Journal: Pediatr Blood Cancer Date: 2010-12-01 Impact factor: 3.167
Authors: David C Hodgson; Melania Pintilie; Leah Gitterman; Beth Dewitt; Carol-Ann Buckley; Sameera Ahmed; Katherine Smith; Amanda Schwartz; Richard W Tsang; Michael Crump; Woodrow Wells; Alexander Sun; Mary K Gospodarowicz Journal: Hematol Oncol Date: 2007-03 Impact factor: 5.271
Authors: Olav Favier; Natacha Heutte; Aspasia Stamatoullas-Bastard; Patrice Carde; Mars B Van't Veer; Berthe M P Aleman; Evert M Noordijk; José Thomas; Christophe Fermé; Michel Henry-Amar Journal: Cancer Date: 2009-04-15 Impact factor: 6.860
Authors: Melissa M Hudson; Daniel A Mulrooney; Daniel C Bowers; Charles A Sklar; Daniel M Green; Sarah S Donaldson; Kevin C Oeffinger; Joseph P Neglia; Anna T Meadows; Leslie L Robison Journal: J Clin Oncol Date: 2009-03-16 Impact factor: 44.544
Authors: S Bhatia; L L Robison; O Oberlin; M Greenberg; G Bunin; F Fossati-Bellani; A T Meadows Journal: N Engl J Med Date: 1996-03-21 Impact factor: 91.245
Authors: Melissa M Hudson; Ann C Mertens; Yutaka Yasui; Wendy Hobbie; Hegang Chen; James G Gurney; Mark Yeazel; Christopher J Recklitis; Neyssa Marina; Leslie R Robison; Kevin C Oeffinger Journal: JAMA Date: 2003-09-24 Impact factor: 157.335
Authors: Joseph M Connors; Wojciech Jurczak; David J Straus; Stephen M Ansell; Won S Kim; Andrea Gallamini; Anas Younes; Sergey Alekseev; Árpád Illés; Marco Picardi; Ewa Lech-Maranda; Yasuhiro Oki; Tatyana Feldman; Piotr Smolewski; Kerry J Savage; Nancy L Bartlett; Jan Walewski; Robert Chen; Radhakrishnan Ramchandren; Pier L Zinzani; David Cunningham; Andras Rosta; Neil C Josephson; Eric Song; Jessica Sachs; Rachael Liu; Hina A Jolin; Dirk Huebner; John Radford Journal: N Engl J Med Date: 2017-12-10 Impact factor: 91.245
Authors: Graça M Dores; Rochelle E Curtis; Nicole H Dalal; Martha S Linet; Lindsay M Morton Journal: J Clin Oncol Date: 2020-09-18 Impact factor: 44.544
Authors: David J Straus; Sin-Ho Jung; Brandelyn Pitcher; Lale Kostakoglu; John C Grecula; Eric D Hsi; Heiko Schöder; Leslie L Popplewell; Julie E Chang; Craig H Moskowitz; Nina Wagner-Johnston; John P Leonard; Jonathan W Friedberg; Brad S Kahl; Bruce D Cheson; Nancy L Bartlett Journal: Blood Date: 2018-07-26 Impact factor: 22.113
Authors: Theresa H M Keegan; Qian Li; Amy Steele; Elysia M Alvarez; Ann Brunson; Christopher R Flowers; Sally L Glaser; Ted Wun Journal: Cancer Causes Control Date: 2018-04-13 Impact factor: 2.532